Browse > Article

An Animal Model to Evaluate the Protective Efficacy of Haemophilus influenzae Type b Conjugate Vaccines  

Kim Hyun Sung (GreenCross Vaccine Corporation)
Yoo Tae Hyeon (GreenCross Vaccine Corporation)
Jang Yang Suk (GreenCross Vaccine Corporation)
Kim Hun (GreenCross Vaccine Corporation)
Park Jin Yong (GreenCross Vaccine Corporation)
Hur Byung Ki (Department of Biotechnology and Bioengineering, Inha University)
Ryu Yeon Woo (Department of Molecular Science and Technology, Ajou University)
Kim Jong Su (GreenCross Vaccine Corporation)
Publication Information
Biotechnology and Bioprocess Engineering:BBE / v.9, no.6, 2004 , pp. 490-494 More about this Journal
Abstract
An efficacy test of PRP (polyribosylribitol phosphate)-TT (Tetanus toxoid) conjugate vaccines was carried out using BALB/c mice as an animal model by inoculating Haemophilus in­fluenzae type b (Hib) with a virulence enhancement factor (VEF). Three administrations of the conjugate vaccines at 2-week intervals elicited a significantly high level of PRP antibodies (P>0.0001). The protective activity of the PRP immunization was challenged with either Hib with iron dextran (Hib/) or with a combination of mucin and hemoglobin (Hibmh) as a VEF. The me­dium lethal dose $(LD_{50})$ for Hibmh and Hibiwas measured as 10 CFU (Colony Forming Unit) and $2.5{\times}10^{8}$ CFU respectively. Each immunized animal was challenged with five or ten times the $LD_{50}$ level of bacteria with a VEF. A significant difference in mortality between the immunized and control mice (P> 0.01) was observed with the Hibmh challenge inoculation but not with the Hibi challenge inoculation. These results show that a combination of mucin and hemoglobin was able to enhance the virulence of Hib in BALB/c mice to cause a lethal infection, thus suggesting that BALB/c mice introduced to this method can be an effective model animal for testing the protective efficacy of H. influenzae conjugate vaccines.
Keywords
Haemophilus influenzae type b; conjugate vaccine; challenge; virulence enhancement agent; combination of mucin and hemoglobin; efficacy;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
Times Cited By Web Of Science : 1  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
1 Burans, J. P., F. H. Kruszeski, M. Lynn, and M. Solotrovsky (1981) Kinetics of Haemophilus influenzae type b infection in normal and ribosom-immunized mice using intraperitoneal and intracerebral routes of inoculation. Br. J. Exp. Pathol. 62: 496-503
2 Kristensen, K, and M. W. Bentzon (1992) Relation be-tween enzyme-linked immunoserbent assay and radioim-munoassay for detection of antibodies to the capsular polysaccharide of Haemophilus influenzae type b. APMIS 100: 142-146   DOI   ScienceOn
3 Miller, C. P. (1933) Experimental meningococcal infection of mice. Science 78: 340-341   DOI   PUBMED
4 Coulehan, J. L., R. H. Michaels, K. E. Williams, D. K. Lemley, C. Q. Jr. North, T. K. Welty, and K. D. Rogers (1976) Bacterial meningitis in Navajo indians. Public Health Rep. 91: 464-468
5 Immunization practices advisory (ACIP) (1986) Update: Prevention of Haemophilus influenzae type b disease. Morbid. Mortal. Week. Rep. 35: 170
6 Heath, P. T. and M. Fracp (1998) Haemophilus influenzae type b conjugate vaccines: A review of efficacy data. Pediatr. Infect. Dis. J. 17: S117-122   DOI   PUBMED
7 Cochi, S. L., C. V. Broome, and A. W. Hightower (1985) Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine. J. Am. Med. Ass. 253: 521-529   DOI   ScienceOn
8 Pittman M. (1933) The action of type-specific H. influenzae antiserum. J. Exp. Med. 58: 683-706   DOI   PUBMED
9 FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children. (1993) Morb. Mortal. Wkly. Rep. 42: 296-298
10 Onodera, M. (2002) Silicone rubber membrane bioreactors for bacterial cellulose production. Biotechnol. Bioprocess Eng. 10: 289-294
11 Moxon, E. R., A. L. Smith, D. R. Averill, and D. H. Smith (1974) Haemophilus influenzae meningitis in infant rats after intranasal inoculation. J. Infect. Dis. 129: 154-162   DOI   ScienceOn
12 Warlaw, A. C. (1985) Practical Statistics for Experimental Biologists. JohnWiley Wiley & Sons Ltd, USA
13 Halesy, N. A., T. L. Johansen, L. C. Bowman, and M. P. Glode (1983) Evaluation of the protective efficacy of Haemophilus influenzae type b vaccines in an animal model. Infec. Immun. 39: 1196-1200
14 Kuo, J. S. C., N. Monji, R. S. Schwalbe, and D. W. McCoy (1981) A radioactive antigen-binding assay for the meas-urement of antibody to Haemophilus influenzae type b capsular polysaccharide. J. Immunol. Methods 43: 35-47   DOI   ScienceOn
15 Granoff, D. M. (2001) Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin. Infect. Dis. 33: S278-287   DOI   ScienceOn
16 Tarr, P. I. and G. Peter (1978) Demographic factors in the epidemiology of Haemophilus influenzae meningitis in young children. J. Pediat. 92: 884-888   DOI
17 Kaplan, S. L., E. O. Mason, Jr., and B. L. Wiedermann (1983) Role of adherence in the pathogenesis of Haemophilus influenzae type b infection in infant rats. Infec. Immun. 42: 612-617
18 Brodeur, B. R., P. S. Tsang, J. Hamel, Y. Larose, and S. Montplaisir (1986) Mouse models of infection for Neisseria meningitides B, 2b and Haemophilus influenzae type b diseases. Can. J. Microbiol. 32: 33-37   DOI   ScienceOn
19 Ward. J. (1991) Prevention of invasive Haemophilus influenzae type b disease: Lessons from vaccine efficacy trials. Vaccine 9: S17-24   DOI   ScienceOn
20 Smith, A. L., D. H. Smith, D. R. Averill, Jr., J. Marino, and E. R. Moxon (1983) Haemophilus influenzae type b bacteremia and meningitis infant rabbits after intranasal inoculation. J. Lab. Clin. Med. 102: 939-946
21 Broueur, B. R., Y. Larose, P. Tsang, J. Hamel, F. Ashton, and A. Ryan (1985) Protection against infection with Neisseria meningitides group B serotype 2b by passive immunization with serotype specific monoclonal antibody. Infect. Immun. 50: 510-516
22 Corbeil, G. A., C. P. Kenny, and G. Laverne (1976) Iron as a replacement for mucin in the establishment of meningococcal infection in mice. Can. J. Microbiol. 22: 832-838   DOI   ScienceOn
23 Rodriguez, S. S., J. F. I. Bourzac, O. M. Chang, M. F. Medina, E. M. Carnago, and Y. L. Hernandez (1999) Virulence enhancement agents for Haemophilus influenzae type b infection in mice. Lab. Anim. Sci. 49: 95-98
24 Farr, R. S. (1958) A quantitative immunochemical measurement of the primary interaction between I*BSA and antibody. J. Infect. Dis. 103: 239-262   DOI   ScienceOn
25 Frasch, C. E. (1994) Regulatory perspectives in vaccine licensure. pp.435-453. In: Ellis R. W, D. W. Granoff (eds.). Development and Clinical Uses of Haemophilus b Conjugate Vaccine. Mercel Dekkar, New York, USA
26 Hong, H. J. and S. T. Kim (2002) Antibody engineering. Biotechnol. Bioprocess Eng. 7: 150-154   DOI   ScienceOn
27 Marks, M. I., E. J. Ziegler, H. Douglas, and L. B. Corbeil (1982) Lethal Haemophilus influenzae type b infection in mice. Infection 10: 261-266   DOI   PUBMED
28 Ward, J., G. Brenneman, G. W. Leston, and W. L. Heyward (1990) Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N. Engl. J. Med. 323: 1391-1401.